Irving-based Reata Pharmaceuticals and Abbott announced that they have entered into a worldwide collaboration to jointly develop and commercialize Reata’s portfolio of second-generation oral antioxidant inflammation modulators. Abbott made a one-time license payment of $400 million to collaborate with Reata. The agreement is in addition to the partnership in which Reata granted to Abbott exclusive rights to develop and commercialize its lead AIM compound, bardoxolone methyl.

Print Friendly